Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Tumor Lysis Syndrome 1Recurrence 1Multiple Myeloma 1Lymphoma 1Hematologic Neoplasms 1

Interventions

Dexamethasone 882Bortezomib 481Lenalidomide 467Cyclophosphamide 367Melphalan 276Calcium Dobesilate 265daratumumab 241pomalidomide 216carfilzomib 188fludarabine phosphate 141fludarabine 137Thalidomide 125Peripheral Blood Stem Cell Transplantation 120Filgrastim 115ixazomib 94Mycophenolic Acid 91Granulocyte Colony-Stimulating Factor 90Busulfan 89Whole-Body Irradiation 88dexamethasone acetate 87Tacrolimus 79dexamethasone 21-phosphate 74isatuximab 70Cyclosporine 68auricularum 67Prednisone 67elotuzumab 63belantamab mafodotin 60Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
AZD0466 × Plasma cell × Clear all
NCT04214093 2023-08-02

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

AstraZeneca

Phase 1 Terminated
9 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Recurrence, Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡